Different Approach Suggested After Progression In NSCLC Patients

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, respectively. However, progression inevitably occurs. When it does, having no clear guidelines and/or indications, most patients are treated with chemotherapy...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/9--kYQl9kts/252910.php

news auto sport medical